BioSpace News Archive

Eli Lilly and Company announced that data from studies of pirtobrutinib, a non-covalent Bruton’s tyrosine kinase inhibitor, will be presented at the 65th American Society of Hematology Annual Meeting and Exposition taking place December 9-12 in San Diego.

HotSpot Therapeutics, Inc. announced it will present preclinical data from the Company’s highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 program in an oral presentation at the 2023 American Society of Hemotology Annual Meeting, taking place December 9-12, 2023, in San Diego, CA.

Chroma Medicine, Inc. announced that it will present a poster demonstrating the potential of its multiplex epigenetic editing platform at the American Society of Hematology 65th Annual Meeting, taking place December 9-12, 2023, in San Diego, CA.

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the creation of the HiFi Solves consortium.

Actinium Pharmaceuticals, Inc. announced that three abstracts detailing results from the completed Phase 3 SIERRA trial of Iomab-B in patients age 55 and above with active relapsed or refractory acute myeloid leukemia have been accepted for presentation at the 65th Annual American Society of Hematology Annual Meeting & Exposition being held in San Diego on December 9-12, 2023.

Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to OMS906, Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 65th Annual Meeting of the American Society of Hematology (ASH), to be held December 9-12, 2023.

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH).

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of abstracts from the IMerge Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS).

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it will present new interim data from its Phase 1/1b trial of soquelitinib in patients with relapsed peripheral T cell lymphoma, at the 65th American Society of Hematology Annual Meeting & Exposition, which is taking place in-person and virtually from December 9-12, 2023.

Harpoon Therapeutics, Inc. announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma.